Innovent Biopharmaceutical Transformation
2021 and 2022 YTD: Another Successful Year
COMMERCIAL
PORTFOLIO
TYVYT
达攸同苏立信
达伯华!達伯坦影
耐立克
D
CYRAMZA™
Sintilimabinjection
******
阿达云单抗注射液
利妥昔单抗注射液
Pemazyre (tablets)
ramucirumab injection
I
TYVYTⓇ
BYVASDAⓇ
SULINNOⓇ
HALPRYZA® I
PemazyreⓇ
奧雷巴替尼 olverembatinib
Olverembatinib
10 mg/mL solution
CYRAMZAⓇ
REGULATORY
ACTIONS
POC
EARLY
INNOVATION
•
BD
•
CMC
•
Innovent
•
new launch
Annual Product Revenue (RMB)
+69.0%
2.4 bn
+133.0%
1.0 bn
REGULATORY APPROVALS
TYVYTⓇ (PD-1): 1L nsqNSCLC, 1L sq NSCLC, 1L HCC
Pemazyre (FGFR): 2L MCCA (Hong Kong, Taiwan)
BYVASDAⓇ (VEGF): 1L HCC, 2L OC, 1L CC
OlverembatinibⓇ (BCR-ABL): CML
POC POSITIVE READOUT (n = 7)
IBI188 (CD47) MDS
IBI310 (CTLA-4) CC/HCC
IBI326 (BCMA CART) MM
IBI344 (ROS1/NTRK) NSCLC
REGULATORY FILINGS
TYVYTⓇ (PD-1) 1L ESCC / 1L GC/2L EGFRm nsqNSCLC
Pemazyre ® (FGFR) 2L MCCA (Mainland China)
RetsevmoⓇ (RET) 2L NSCLC/MTC/TC
IBI362 (OXM3) Obesity / Diabetes
IBI302 (VEGF/complement) nAMD
IBI112 (IL-23 p19) Psoriasis
•
POC STUDIES ONGOING/UPCOMING (n = 6)
IBI110 (LAG-3)
IBI322 (PD-L1/CD47)
IBI939 (TIGIT)
IBI315 (PD-1/HER2)
IBI351 (KRAS G12C)
IBI323 (PD-L1/LAG3)
80+ research programs for 7 taskforces focusing on antibody protein engineering, immunology and cancer biology
Delivered 7 molecules advancing into the clinic within 1-2 years
Expanding talent structure and established SAB (scientist advisory board) contributing to true innovation
AnHeart
Therapeutics
薙方压药
Ascentage Pharma
GENFLEET
BOLT
BIOTHERAPEUTICS
Synaffix
4.0 bn
2019
2020
2021
UNION
THERAPEUTICS
Lilly
Completed construction of another 36,000L manufacturing capacity to reach a total of 60,000L for antibody production.
Established world-class CMC Strategic Advisory Board with strong support from global renowned top experts.
Confidential
Copyright©2022 Innovent
LO
5View entire presentation